SCHEMBL4112432

SCHEMBL4112432

CCCc1nc(N)nc2ccc(-c3ccccc3NS(=O)(=O)c3ccc(C)cc3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
LMNA P02545 5/20 0.49
ALDH1A1 P00352 4/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2C19 P33261 3/20 0.49
POLB P06746 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
USP2 O75604 1/20 0.49
NOD2 Q9HC29 1/20 0.49
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
CA12 O43570 1/20 0.46
MCOLN3 Q8TDD5 1/20 0.46
KMT2A Q03164 8/20 0.40
MEN1 O00255 7/20 0.40
NPSR1 Q6W5P4 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
HTT P42858 2/20 0.40
MITF O75030 1/20 0.40
S1PR4 O95977 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4102492 0.88 LMNA (0.48) MAPTLMNAALDH1A1CYP2C9CYP2C19
SCHEMBL4102757 0.87 PDE5A (0.48) MAPTPOLBKMT2AMEN1HTT
SCHEMBL4102185 0.82 LMNA (0.56) MAPTLMNAALDH1A1CYP2C9CYP2C19
SCHEMBL4112723 0.82 MAPT (0.48) MAPTLMNAALDH1A1USP2KMT2A
SCHEMBL4095764 0.79 MEN1 (0.40) MAPTLMNAALDH1A1POLBKMT2A
SCHEMBL4101899 0.76 ALOX5AP (0.36) CYP2C9CA2CA9CA12CA1
SCHEMBL4105834 0.74 DHFR (0.34)
SCHEMBL4112715 0.74 KDM1A (0.40) LMNAPOLBKMT2AMEN1SMN1; SMN2
SCHEMBL4115509 0.73 PTPN1 (0.48) MAPTALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL4113503 0.72 MAPT (0.53) MAPTLMNAALDH1A1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338435-B2 Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections GILEAD SCIENCES, INC. (US) 2012-12-25 US claimed
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 US claimed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8338435-B2 Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections GILEAD SCIENCES, INC. (US) 2012-12-25 US disclosed
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2009-10-08 US disclosed
WO-2008009076-A2 SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253696-A1 SUBSTITUTED PYRIDO(3,2-D) PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS PNPO, PNP, DPYD MAPT 1752/4885LMNA 1233/4885ALDH1A1 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.